^
    Back
    Association details:
    Biomarker:MET fusion
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug:Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    ASCO 2018
    Title:

    Comprehensive genomic profiling in Chinese patients with clear cell renal cell carcinoma.

    Published date:
    05/16/2018
    Excerpt:
    Deep sequencing targeting 450 cancer genes was performed on FFPE and matched blood samples collected from 39 Chinese ccRCC pts...One pt with a novel MET fusion responded well to cabozantinib.
    DOI:
    10.1200/JCO.2018.36.15_suppl.e13517